Go Pro
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$29.73
+0.5%		$26.48
$19.69
▼
$30.96
$5.10B0.811.82 million shs879,335 shs
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$249.36
-0.4%		$255.02
$186.05
▼
$282.15
$15.61B0.39517,508 shs189,533 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
-3.24%-2.09%+16.50%+36.75%+15.01%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-1.08%-3.61%-1.25%+5.38%+27.25%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$29.73
+0.5%		$26.48
$19.69
▼
$30.96
$5.10B0.811.82 million shs879,335 shs
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$249.36
-0.4%		$255.02
$186.05
▼
$282.15
$15.61B0.39517,508 shs189,533 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
-3.24%-2.09%+16.50%+36.75%+15.01%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-1.08%-3.61%-1.25%+5.38%+27.25%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
2.78
Moderate Buy$34.3615.58% Upside
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.05
Buy$302.6821.38% Upside

Current Analyst Ratings Breakdown

Latest ACAD and ASND Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/27/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$345.00
8/25/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$37.00 ➝ $38.00
8/25/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$27.00 ➝ $28.00
8/25/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$39.00 ➝ $40.00
8/18/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$319.00
8/18/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$319.00
8/17/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$45.00 ➝ $49.00
8/14/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$280.00 ➝ $290.00
8/14/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$325.00 ➝ $341.00
8/14/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$345.00 ➝ $329.00
8/13/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$333.00
(Data available from 8/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$1.07B4.78$0.89 per share33.34$7.58 per share3.92
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$814.57M19.10N/AN/A$26.78 per share9.31
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$391M$2.2247.7130.3422.0633.42%9.03%6.79%11/4/2026 (Estimated)
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$258M$12.89139.0324.91N/A70.99%32.54%7.71%11/11/2026 (Estimated)

Latest ACAD and ASND Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$1.71$1.0270-$0.6830$3.23$376.75 million$387.22 million
8/4/2026Q2 2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$0.0682$0.18+$0.1119$0.18$296.55 million$308.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/AN/AN/AN/AN/A
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/A
3.39
3.30
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.27
2.99
2.32

Institutional Ownership

CompanyInstitutional Ownership
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
96.71%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A

Insider Ownership

CompanyInsider Ownership
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
26.20%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
510172.31 million127.16 millionOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,18962.38 million37.43 millionOptionable

Recent News About These Companies

Ascendis Pharma Earnings Call Highlights Blockbuster Momentum
August 26 at 3:15 PM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ASND/pressreleases/4047999/ascendis-pharma-earnings-call-highlights-blockbuster-momentum/
Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026
August 25 at 4:01 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/25/3350865/0/en/ascendis-announces-oral-presentation-of-week-104-data-from-its-pivotal-trial-of-transcon-cnp-navepegritide-at-isds-2026.html
Ascendis Pharma (ASND) Receives a Buy from Morgan Stanley
August 25 at 9:32 AM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/4020655/ascendis-pharma-asnd-receives-a-buy-from-morgan-stanley/
Ascendis Pharma (ASND): Three New Drugs Are Turning This Biotech Into A Growth Machine
August 21, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/ascendis-pharma-asnd-three-drugs-214640196.html
Ascendis Pharma (ASND) Q2 2026 Earnings Call Transcript
August 20, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/ascendis-pharma-asnd-q2-2026-132925835.html
Ascendis Pharma A/S (NASDAQ:ASND) Upgraded to Strong-Buy at BMO Capital Markets
August 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/ascendis-pharma-as-nasdaqasnd-upgraded-to-strong-buy-at-bmo-capital-markets-2026-08-20/
Ascendis Pharma A/S (NASDAQ:ASND) Director Jean Jacques Bienaime Buys 2,000 Shares
August 19, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-asnd-insider-buying-and-selling-2026-08-19/
Ascendis Pharma A/S (NASDAQ:ASND) Director Jean Jacques Bienaime Purchases 2,000 Shares of Stock
August 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/ascendis-pharma-as-nasdaqasnd-director-jean-jacques-bienaime-purchases-2000-shares-of-stock-2026-08-18/
Eyconis Announces Initiation of First-in-Human Clinical Trial of EYC-0305 in Treatment-Naïve Wet Age-Related Macular Degeneration Patients
August 18, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/18/3346753/0/en/eyconis-announces-initiation-of-first-in-human-clinical-trial-of-eyc-0305-in-treatment-na%c3%afve-wet-age-related-macular-degeneration-patients.html
Ascendis Pharma Reports Solid Yorvipath Quarter; Yuviwel Off to Strong Start, RBC Says
August 16, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/ascendis-pharma-reports-solid-yorvipath-152749820.html
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Ascendis Pharma (ASND)
August 15, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/LLY/pressreleases/3864471/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-ascendis-pharma-asnd/
Ascendis Pharma A/S (NASDAQ:ASND) Upgraded at Wall Street Zen
August 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/ascendis-pharma-as-nasdaqasnd-upgraded-at-wall-street-zen-2026-08-15/
Ascendis Pharma A/S (NASDAQ:ASND) Releases Quarterly Earnings Results, Misses Estimates By $0.68 EPS
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/ascendis-pharma-as-nasdaqasnd-releases-quarterly-earnings-results-misses-estimates-by-068-eps-2026-08-14/
Ascendis Pharma AS (ASND) (Q2 2026) Earnings Call Highlights: Revenue Doubles to EUR315 ...
August 14, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/ascendis-pharma-asnd-q2-2026-230911305.html
Full Transcript: Ascendis Pharma Q2 2026 Earnings Call
August 13, 2026  |  benzinga.comhttps://www.benzinga.com/news/26/08/61174628/full-transcript-ascendis-pharma-q2-2026-earnings-call
Ascendis Pharma's Q2 Adjusted Earnings, Revenue Rise
August 13, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/ascendis-pharma-apos-q2-adjusted-120833096.html
Ascendis Pharma A/S Q2 Earnings Call Highlights
August 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/ascendis-pharma-as-q2-earnings-call-highlights-2026-08-13/
Ascendis Pharma Files Strong Interim Q2 2026 Results on Form 6-K
August 13, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/ascendis-pharma-files-strong-interim-q2-2026-results-on-form-6-k?utm_source=marketbeat.com&utm_medium=referral
Ascendis Pharma Reports Second Quarter 2026 Financial Results
August 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/13/3344408/0/en/ascendis-pharma-reports-second-quarter-2026-financial-results.html
Ascendis Pharma A/S (NASDAQ:ASND) Receives Average Recommendation of "Buy" from Analysts
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/ascendis-pharma-as-nasdaqasnd-receives-average-recommendation-of-buy-from-analysts-2026-08-07/
Ascendis Pharma Seeing 'Good Progress' in Achondroplasia Programs, Wedbush Says
August 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/ascendis-pharma-seeing-apos-good-160517080.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACADIA Pharmaceuticals stock logo

ACADIA Pharmaceuticals NASDAQ:ACAD

$29.73 +0.15 (+0.51%)
Closing price 04:00 PM Eastern
Extended Trading
$29.70 -0.03 (-0.10%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$249.36 -0.89 (-0.36%)
Closing price 04:00 PM Eastern
Extended Trading
$249.35 -0.01 (0.00%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas